Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ZD-6474. AstraZeneca.

David Bates1

  • 1Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, University of Bristol, Southwell Street, Bristol, BS2 8EJ, UK. Dave.Bates@bris.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|February 7, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Initial specialist validation of clinical decision support recommendations from a machine learning-enabled digital cognitive assessment.

Frontiers in neurology·2026
Same author

Real-world implementation of clinical decision support systems in emergency departments: a scoping review protocol.

JBI evidence synthesis·2026
Same author

Subarachnoid trabeculae suppress cerebrospinal fluid pressurization during translational impact loading using instrumented biomimetic head surrogates.

Acta biomaterialia·2026
Same author

Streamlining Eligibility Assessment for Alzheimer's Disease-Modifying Therapies: Prediction of MMSE Scores Using the Digital Clock and Recall.

medRxiv : the preprint server for health sciences·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

ZD-6474, a dual inhibitor of vascular endothelial growth factor and epidermal growth factor receptor tyrosine kinases, is being developed for solid tumors. Phase II trials are underway for non-small-cell lung cancer, small-cell lung cancer, and myeloma.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • ZD-6474 is an inhibitor targeting vascular endothelial growth factor receptor (VEGFR) tyrosine kinase.
  • It also exhibits inhibitory activity against epidermal growth factor receptor (EGFR) tyrosine kinase.
  • AstraZeneca is developing ZD-6474 for the potential treatment of various solid tumors.

Purpose of the Study:

  • To evaluate the efficacy and safety of ZD-6474 in patients with solid tumors.
  • To assess the drug's potential in treating specific cancer types including non-small-cell lung cancer, small-cell lung cancer, and myeloma.

Main Methods:

  • Phase II clinical trials were initiated to investigate ZD-6474.
  • The trials focused on patient populations with non-small-cell lung cancer, small-cell lung cancer, and myeloma.

Related Experiment Videos

Main Results:

  • Clinical trials were ongoing as of January 2003, indicating active investigation.
  • Specific efficacy and safety results from the Phase II trials are not detailed in this abstract.

Conclusions:

  • ZD-6474 represents a targeted therapy approach for solid tumors.
  • Further clinical development is necessary to determine its therapeutic value and optimal use.